首页 > 最新文献

Primary Care Respiratory Journal最新文献

英文 中文
Are we misleading users of respiratory spacer devices? 我们是否在误导呼吸间隔器的使用者?
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00103
Mark J Sanders, Ronald Bruin
VHC whistles would be activated if the patient goes beyond a flow rate of 60 L/min (the top end of the ideal inspiratory flow rate). However, our research with three whistle-containing VHCs suggests that this appears to be an erroneous assumption and, unwittingly, we may be misleading patients and therefore contributing to reduced patient care. We measured the whistle-activation flow rates for three different makes of VHCs: Able Spacer (Clement Clarke), AeroChamber Plus (GSK), and Optichamber Diamond (Philips Respironics). A calibrated waveform generator (Pulmonary Waveform Generator System, MH Custom Design & Mfg L.C., Utah, USA) was used to create a standardised vacuum force similar to a human inhalation. The performance of three samples of each device was assessed when used with a range of popular drug pMDIs (see Table). The vacuum force was repeated at 1 L/min incremental amounts until the VHCwhistle sounded. Two operatives agreed the whistle sounding. Three recordings of each VHC-drug pMDI combination were carried out (n=54 tests) and the flow rates recorded. The data show that there is a wide variation in the performance of a VHC-whistle as a function of the inhaler to which it is attached. In many instances the whistle first activates at a flow rate well beyond what would be considered acceptable in order to promote effective drug deposition. This phenomenon can be explained. When the patient inhales from the VHC, air will be drawn in through a combination of two routes – the whistle, and the channels surrounding the canister of Dear Sirs, The UK Drug Tariff lists a number of spacer and valved holding chamber (VHC) products for use with pressurised metered dose inhalers (pMDIs). These add-on devices have the double objective of improving the delivery of drug, and making the inhalation procedure easier for the patient. VHCs, in particular, help the user by eliminating the requirement that the slow deep inspiration coincides with the actuation of the pMDI – a manoeuvre which can be particularly tricky for children and the elderly, although poor coordination is worryingly common in pMDI users irrespective of age. VHC users should inhale gently, using either tidal breathing or an approximate 30 L/min inspiratory flow, which facilitates lung deposition of the drug particles. Some VHC products include an alert whistle designed to sound “when the patient is breathing in too quickly”, as this type of forceful inspiratory manoeuvre increases the likelihood of oral/pharyngeal drug deposition. It is known that healthcare trainers use the whistle-alert as a tool to titrate the Prim Care Respir J 2013; 22(4): 466-467
{"title":"Are we misleading users of respiratory spacer devices?","authors":"Mark J Sanders, Ronald Bruin","doi":"10.4104/pcrj.2013.00103","DOIUrl":"https://doi.org/10.4104/pcrj.2013.00103","url":null,"abstract":"VHC whistles would be activated if the patient goes beyond a flow rate of 60 L/min (the top end of the ideal inspiratory flow rate). However, our research with three whistle-containing VHCs suggests that this appears to be an erroneous assumption and, unwittingly, we may be misleading patients and therefore contributing to reduced patient care. We measured the whistle-activation flow rates for three different makes of VHCs: Able Spacer (Clement Clarke), AeroChamber Plus (GSK), and Optichamber Diamond (Philips Respironics). A calibrated waveform generator (Pulmonary Waveform Generator System, MH Custom Design & Mfg L.C., Utah, USA) was used to create a standardised vacuum force similar to a human inhalation. The performance of three samples of each device was assessed when used with a range of popular drug pMDIs (see Table). The vacuum force was repeated at 1 L/min incremental amounts until the VHCwhistle sounded. Two operatives agreed the whistle sounding. Three recordings of each VHC-drug pMDI combination were carried out (n=54 tests) and the flow rates recorded. The data show that there is a wide variation in the performance of a VHC-whistle as a function of the inhaler to which it is attached. In many instances the whistle first activates at a flow rate well beyond what would be considered acceptable in order to promote effective drug deposition. This phenomenon can be explained. When the patient inhales from the VHC, air will be drawn in through a combination of two routes – the whistle, and the channels surrounding the canister of Dear Sirs, The UK Drug Tariff lists a number of spacer and valved holding chamber (VHC) products for use with pressurised metered dose inhalers (pMDIs). These add-on devices have the double objective of improving the delivery of drug, and making the inhalation procedure easier for the patient. VHCs, in particular, help the user by eliminating the requirement that the slow deep inspiration coincides with the actuation of the pMDI – a manoeuvre which can be particularly tricky for children and the elderly, although poor coordination is worryingly common in pMDI users irrespective of age. VHC users should inhale gently, using either tidal breathing or an approximate 30 L/min inspiratory flow, which facilitates lung deposition of the drug particles. Some VHC products include an alert whistle designed to sound “when the patient is breathing in too quickly”, as this type of forceful inspiratory manoeuvre increases the likelihood of oral/pharyngeal drug deposition. It is known that healthcare trainers use the whistle-alert as a tool to titrate the Prim Care Respir J 2013; 22(4): 466-467","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31897435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis. 哮喘患者不能正确使用加压计量吸入器(pMDI)与全球哮喘行动(GINA)战略所定义的哮喘控制不良相关:一项回顾性分析。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00084
Mark L Levy, Alison Hardwell, Eddie McKnight, John Holmes

Background: In practice it is logical that inhalers are prescribed only after patients have received training and demonstrated their ability to use the device. However, many patients are unable to use their pressurised metered-dose inhaler devices (pMDIs) correctly. We assessed the relationship between asthma control and patients' ability to use their prescribed pMDIs.

Methods: Evaluation of 3,981 (46% male) primary care asthma patient reviews, which included inhaler technique and asthma control, by specialist nurses in primary care in 2009. The paper focuses on people currently prescribed pMDI devices.

Results: Accurate data on reliever and preventer inhaler prescriptions were available for 3,686 and 2,887 patients, respectively. In patients prescribed reliever inhalers, 2,375 (64%) and 525 (14%) were on pMDI alone or pMDI plus spacer, respectively. For those prescribed preventers, 1,976 (68%) and 171 (6%) were using a pMDI without and with a spacer, respectively. Asthma was controlled in 50% of patients reviewed. The majority of patients (60% of 3,686) were using reliever pMDIs, 13% with spacers. Incorrect pMDI use was associated with poor asthma control (p<0.0001) and more short burst systemic steroid prescriptions in the last year (p=0.038). Of patients using beclometasone (the most frequently prescribed preventer drug in our sample), significantly more of those using a breath-actuated pMDI device (p<0.0001) and a spacer (p<0.0001) were controlled compared with those on pMDIs alone.

Conclusions: Patients who are able to use pMDIs correctly have better asthma control as defined by the GINA strategy document. Beclometasone via a spacer or breath-actuated device resulted in better asthma control than via a pMDI alone. Patients prescribed pMDIs should be carefully instructed in technique and have their ability to use these devices tested; those unable to use the device should be prescribed a spacer or an alternative device such as one that is breath-actuated.

背景:在实践中,只有在患者接受培训并证明他们有能力使用吸入器后才开吸入器是合乎逻辑的。然而,许多患者不能正确使用他们的加压计量吸入器(pmdi)。我们评估了哮喘控制与患者使用处方pmdi的能力之间的关系。方法:对2009年初级保健专科护士对3981例(46%男性)初级保健哮喘患者的评价,包括吸入器技术和哮喘控制。本文的重点是目前使用pMDI设备的人。结果:分别为3,686例和2,887例患者提供了缓解剂和预防剂吸入剂处方的准确数据。在处方缓解吸入器的患者中,分别有2375例(64%)和525例(14%)单独使用pMDI或pMDI加间隔剂。对于指定的防喷剂,分别有1976(68%)和171(6%)使用不带隔离剂和带隔离剂的pMDI。50%的患者哮喘得到控制。大多数患者(3686名患者中的60%)使用缓解性pmdi, 13%使用间隔剂。不正确使用pMDI与哮喘控制不良相关(结论:能够正确使用pMDI的患者具有GINA策略文件定义的更好的哮喘控制。通过间隔器或呼吸驱动装置使用倍氯米松比单独使用pMDI效果更好。处方pmdi的患者应在技术上仔细指导,并对其使用这些装置的能力进行测试;那些不能使用该设备的人应该开一个间隔器或一个替代设备,比如呼吸驱动的设备。
{"title":"Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the global initiative for asthma (GINA) strategy: a retrospective analysis.","authors":"Mark L Levy,&nbsp;Alison Hardwell,&nbsp;Eddie McKnight,&nbsp;John Holmes","doi":"10.4104/pcrj.2013.00084","DOIUrl":"https://doi.org/10.4104/pcrj.2013.00084","url":null,"abstract":"<p><strong>Background: </strong>In practice it is logical that inhalers are prescribed only after patients have received training and demonstrated their ability to use the device. However, many patients are unable to use their pressurised metered-dose inhaler devices (pMDIs) correctly. We assessed the relationship between asthma control and patients' ability to use their prescribed pMDIs.</p><p><strong>Methods: </strong>Evaluation of 3,981 (46% male) primary care asthma patient reviews, which included inhaler technique and asthma control, by specialist nurses in primary care in 2009. The paper focuses on people currently prescribed pMDI devices.</p><p><strong>Results: </strong>Accurate data on reliever and preventer inhaler prescriptions were available for 3,686 and 2,887 patients, respectively. In patients prescribed reliever inhalers, 2,375 (64%) and 525 (14%) were on pMDI alone or pMDI plus spacer, respectively. For those prescribed preventers, 1,976 (68%) and 171 (6%) were using a pMDI without and with a spacer, respectively. Asthma was controlled in 50% of patients reviewed. The majority of patients (60% of 3,686) were using reliever pMDIs, 13% with spacers. Incorrect pMDI use was associated with poor asthma control (p<0.0001) and more short burst systemic steroid prescriptions in the last year (p=0.038). Of patients using beclometasone (the most frequently prescribed preventer drug in our sample), significantly more of those using a breath-actuated pMDI device (p<0.0001) and a spacer (p<0.0001) were controlled compared with those on pMDIs alone.</p><p><strong>Conclusions: </strong>Patients who are able to use pMDIs correctly have better asthma control as defined by the GINA strategy document. Beclometasone via a spacer or breath-actuated device resulted in better asthma control than via a pMDI alone. Patients prescribed pMDIs should be carefully instructed in technique and have their ability to use these devices tested; those unable to use the device should be prescribed a spacer or an alternative device such as one that is breath-actuated.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31737975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 125
The quality of reporting of randomised controlled trials in asthma: a systematic review. 哮喘随机对照试验的报告质量:系统综述。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00089
Chara Ntala, Panagiota Birmpili, Allison Worth, Niall H Anderson, Aziz Sheikh

Background: There are concerns about the reporting quality of asthma trials.

Aims: To describe the reporting of contemporary asthma trials and to identify factors associated with better reporting quality.

Methods: Two reviewers independently searched MEDLINE for randomised controlled trials (RCTs) of asthma published between January 2010 and July 2012 in leading generalist and specialist journals. We calculated the proportion of trials that adequately reported each Consolidated Standards of Reporting Trials (CONSORT) checklist item and an overall quality score for each trial. Factors associated with better reporting quality were investigated.

Results: Thirty-five RCTs satisfied our eligibility criteria. Four trials adequately reported <50% of the items, 15 adequately reported 50-60% of items, and 16 adequately reported >60% of items. Seventeen of the 38 CONSORT items were consistently well reported in more than two-thirds of the articles. In contrast, nine items were poorly reported in more than half the trials - namely, identification as a randomised trial in the title (40.0%), an adequate structured summary/abstract (48.6%), details of eligibility criteria (34.3%), recruitment (48.6%), randomisation procedures (22.9%), intervention (38.5%), harms (34.3%), the funding source (45.7%), and access to the full trial protocol (17.1%). Studies led by teams in high-income country settings were associated with better quality of reporting (relative risk=1.33, 95% CI 1.09 to 1.64).

Conclusions: The quality of reporting in contemporary asthma literature remains suboptimal. We have identified important areas in which reporting quality needs to be improved.

背景:哮喘试验的报告质量令人担忧:目的:描述当代哮喘试验的报告情况,并找出提高报告质量的相关因素:两名审稿人独立检索了MEDLINE,以查找2010年1月至2012年7月期间发表在主要综合和专业期刊上的哮喘随机对照试验(RCT)。我们计算了充分报告了《试验报告统一标准》(CONSORT)检查表中每项内容的试验比例以及每项试验的总体质量得分。我们还调查了与提高报告质量相关的因素:35项RCT符合我们的资格标准。四项试验充分报告了 60% 的项目。在 38 个 CONSORT 项目中,有 17 个项目在三分之二以上的文章中得到了充分报告。相比之下,半数以上的试验对九项内容的报告较差,即标题中的随机试验标识(40.0%)、充分的结构化摘要/摘要(48.6%)、资格标准的细节(34.3%)、招募(48.6%)、随机化程序(22.9%)、干预(38.5%)、危害(34.3%)、资金来源(45.7%)以及完整试验方案的获取(17.1%)。由高收入国家团队领导的研究与较高的报告质量有关(相对风险=1.33,95% CI 1.09至1.64):结论:当代哮喘文献的报告质量仍然不尽如人意。结论:当代哮喘文献的报道质量仍然不尽如人意,我们发现了需要提高报道质量的重要领域。
{"title":"The quality of reporting of randomised controlled trials in asthma: a systematic review.","authors":"Chara Ntala, Panagiota Birmpili, Allison Worth, Niall H Anderson, Aziz Sheikh","doi":"10.4104/pcrj.2013.00089","DOIUrl":"10.4104/pcrj.2013.00089","url":null,"abstract":"<p><strong>Background: </strong>There are concerns about the reporting quality of asthma trials.</p><p><strong>Aims: </strong>To describe the reporting of contemporary asthma trials and to identify factors associated with better reporting quality.</p><p><strong>Methods: </strong>Two reviewers independently searched MEDLINE for randomised controlled trials (RCTs) of asthma published between January 2010 and July 2012 in leading generalist and specialist journals. We calculated the proportion of trials that adequately reported each Consolidated Standards of Reporting Trials (CONSORT) checklist item and an overall quality score for each trial. Factors associated with better reporting quality were investigated.</p><p><strong>Results: </strong>Thirty-five RCTs satisfied our eligibility criteria. Four trials adequately reported <50% of the items, 15 adequately reported 50-60% of items, and 16 adequately reported >60% of items. Seventeen of the 38 CONSORT items were consistently well reported in more than two-thirds of the articles. In contrast, nine items were poorly reported in more than half the trials - namely, identification as a randomised trial in the title (40.0%), an adequate structured summary/abstract (48.6%), details of eligibility criteria (34.3%), recruitment (48.6%), randomisation procedures (22.9%), intervention (38.5%), harms (34.3%), the funding source (45.7%), and access to the full trial protocol (17.1%). Studies led by teams in high-income country settings were associated with better quality of reporting (relative risk=1.33, 95% CI 1.09 to 1.64).</p><p><strong>Conclusions: </strong>The quality of reporting in contemporary asthma literature remains suboptimal. We have identified important areas in which reporting quality needs to be improved.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31879047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acceptance and practicability of a visual communication tool in smoking cessation counselling: a randomised controlled trial. 视觉交流工具在戒烟咨询中的接受度和实用性:一项随机对照试验。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00086
Stefan Neuner-Jehle, Marianne I Knecht, Claudia Stey-Steurer, Oliver Senn

Background: Smoking cessation advice is important for reducing the worldwide burden of disease resulting from tobacco smoking. Appropriate risk communication formats improve the success of counselling interventions in primary care.

Aims: To test the feasibility and acceptance of a smoking cessation counselling tool with different cardiovascular risk communication formats including graphs, in comparison with the International Primary Care Respiratory Group (IPCRG) 'quit smoking assistance' tool.

Methods: GPs were randomised into an intervention group (using our communication tool in addition to the IPCRG sheet) and a control group (using the IPCRG sheet only). We asked participants for socioeconomic data, smoking patterns, understanding of information, motivation, acceptance and feasibility, and measured the duration and frequency of counselling sessions.

Results: Twenty-five GPs performed 2.8 counselling sessions per month in the intervention group and 1.7 in the control group (p=0.3) with 114 patients. The median duration of a session was 10 mins (control group 11 mins, p=0.09 for difference). Median patients' motivation for smoking cessation was 7 on a 10-point visual analogue scale with no significant difference before and after the intervention (p=0.2) or between groups (p=0.73 before and p=0.15 after the intervention). Median patients' ratings of motivation, selfconfidence, understanding of information, and satisfaction with the counselling were 3-5 on a 5-point Likert scale, similar to GPs' ratings of acceptance and feasibility, with no significant difference between groups.

Conclusions: Among Swiss GPs and patients, both our innovative communication tool and the IPCRG tool were well accepted and both merit further dissemination and application in research.

背景:戒烟建议对于减轻世界范围内吸烟引起的疾病负担很重要。适当的风险沟通形式可提高初级保健咨询干预措施的成功率。目的:与国际初级保健呼吸系统小组(IPCRG)的“戒烟援助”工具相比,测试具有不同心血管风险沟通格式(包括图表)的戒烟咨询工具的可行性和可接受性。方法:全科医生被随机分为干预组(除了IPCRG表外,还使用我们的沟通工具)和对照组(仅使用IPCRG表格)。我们询问了参与者的社会经济数据、吸烟模式、对信息的理解、动机、接受度和可行性,并测量了咨询会议的持续时间和频率。结果:干预组25名全科医生每月进行2.8次咨询,对照组1.7次(p=0.03),共114名患者。疗程的中位持续时间为10分钟(对照组为11分钟,差异p=0.09)。在10点视觉模拟量表上,患者戒烟动机的中位数为7,干预前后或组间无显著差异(干预前p=0.73,干预后p=0.15)。在5分Likert量表中,患者对动机、自信心、对信息的理解和对咨询的满意度的中位评分为3-5,与全科医生对接受度和可行性的评分相似,各组之间没有显著差异。结论:在瑞士全科医生和患者中,我们的创新沟通工具和IPCRG工具都被广泛接受,都值得在研究中进一步传播和应用。
{"title":"Acceptance and practicability of a visual communication tool in smoking cessation counselling: a randomised controlled trial.","authors":"Stefan Neuner-Jehle,&nbsp;Marianne I Knecht,&nbsp;Claudia Stey-Steurer,&nbsp;Oliver Senn","doi":"10.4104/pcrj.2013.00086","DOIUrl":"10.4104/pcrj.2013.00086","url":null,"abstract":"<p><strong>Background: </strong>Smoking cessation advice is important for reducing the worldwide burden of disease resulting from tobacco smoking. Appropriate risk communication formats improve the success of counselling interventions in primary care.</p><p><strong>Aims: </strong>To test the feasibility and acceptance of a smoking cessation counselling tool with different cardiovascular risk communication formats including graphs, in comparison with the International Primary Care Respiratory Group (IPCRG) 'quit smoking assistance' tool.</p><p><strong>Methods: </strong>GPs were randomised into an intervention group (using our communication tool in addition to the IPCRG sheet) and a control group (using the IPCRG sheet only). We asked participants for socioeconomic data, smoking patterns, understanding of information, motivation, acceptance and feasibility, and measured the duration and frequency of counselling sessions.</p><p><strong>Results: </strong>Twenty-five GPs performed 2.8 counselling sessions per month in the intervention group and 1.7 in the control group (p=0.3) with 114 patients. The median duration of a session was 10 mins (control group 11 mins, p=0.09 for difference). Median patients' motivation for smoking cessation was 7 on a 10-point visual analogue scale with no significant difference before and after the intervention (p=0.2) or between groups (p=0.73 before and p=0.15 after the intervention). Median patients' ratings of motivation, selfconfidence, understanding of information, and satisfaction with the counselling were 3-5 on a 5-point Likert scale, similar to GPs' ratings of acceptance and feasibility, with no significant difference between groups.</p><p><strong>Conclusions: </strong>Among Swiss GPs and patients, both our innovative communication tool and the IPCRG tool were well accepted and both merit further dissemination and application in research.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31790394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
A woman with breathlessness: a practical approach to diagnosis and management. 一位患有呼吸困难的女性:一种实用的诊断和治疗方法。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00100
Alan Kaplan, Kevin Gruffydd-Jones, Frederik van Gemert, Bruce J Kirenga, Andrew R L Medford

Worsening breathless in a patient with severe chronic obstructive pulmonary disease (COPD) is a common diagnostic and management challenge in primary care. A systematic approach to history-taking and examination combined with targeted investigation of pulmonary, cardiovascular, thromboembolic and systemic causes is essential if co-morbidities are to be identified and managed. Distinguishing between heart failure and COPD is a particular challenge as symptoms and signs overlap. In low and middle income countries additional priorities are the detection of infections such as tuberculosis and human immunodeficiency virus (HIV). Clinicians need to be alert to the possibility of atypical presentations (such as pain-free variants of angina) and less common conditions (including chronic thromboembolic pulmonary hypertension) in order not to overlook important potentially treatable conditions.

严重慢性阻塞性肺病(COPD)患者呼吸困难加重是初级保健中常见的诊断和管理挑战。如果要识别和管理合并症,就必须采用系统的病史采集和检查方法,并有针对性地调查肺部、心血管、血栓栓塞和全身原因。由于症状和体征重叠,区分心力衰竭和慢性阻塞性肺病是一项特别的挑战。在中低收入国家,其他优先事项是检测结核病和人体免疫缺陷病毒等感染。临床医生需要警惕非典型表现(如心绞痛的无痛变体)和不太常见的疾病(包括慢性血栓栓塞性肺动脉高压)的可能性,以免忽视重要的潜在可治疗疾病。
{"title":"A woman with breathlessness: a practical approach to diagnosis and management.","authors":"Alan Kaplan, Kevin Gruffydd-Jones, Frederik van Gemert, Bruce J Kirenga, Andrew R L Medford","doi":"10.4104/pcrj.2013.00100","DOIUrl":"10.4104/pcrj.2013.00100","url":null,"abstract":"<p><p>Worsening breathless in a patient with severe chronic obstructive pulmonary disease (COPD) is a common diagnostic and management challenge in primary care. A systematic approach to history-taking and examination combined with targeted investigation of pulmonary, cardiovascular, thromboembolic and systemic causes is essential if co-morbidities are to be identified and managed. Distinguishing between heart failure and COPD is a particular challenge as symptoms and signs overlap. In low and middle income countries additional priorities are the detection of infections such as tuberculosis and human immunodeficiency virus (HIV). Clinicians need to be alert to the possibility of atypical presentations (such as pain-free variants of angina) and less common conditions (including chronic thromboembolic pulmonary hypertension) in order not to overlook important potentially treatable conditions. </p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31897436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK. 患者对哮喘控制的感知与现实世界症状之间的持续差异:一项对来自英国的1,083名哮喘成年人的定量在线调查。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00091
Monica Fletcher, David Hiles

Background: Previous studies have identified a discrepancy between patient perception of asthma control and real-world symptoms; despite several hypotheses, the reasons remain unclear.

Aims: To explore patients' experiences of asthma symptoms and disease management and their educational needs in the UK; to assess recent progress in asthma control and management.

Methods: A quantitative questionnaire-based online survey of UK patients aged >18 years with self-reported asthma.

Results: Of the 1,083 individuals (55% female, 49% aged >55 years) who completed the survey, 79% described their asthma control as 'good' or 'very good'. Despite this, in the previous 2 years, 65% had experienced 'frequent' day-time symptoms, 37% had 'frequent' night-time symptoms, and 25% had used oral steroids for asthma; 41% of those prescribed a reliever inhaler used it >1 a day. Overall, 76% had a 'good' or 'very good' relationship with their healthcare professional (HCP); 32% had not attended regular asthma reviews and only 12% were using a personal asthma action plan. Moreover, 70% of respondents felt that they had the 'main responsibility' for managing their asthma; 29% believed this responsibility to be shared with their HCP.

Conclusions: This survey indicates a continuing discrepancy between patient perception of asthma control and real-world symptoms, with little change from previous studies. Many patients accept symptoms as the norm. The diversity among respondents' attitudes demonstrates a need to help patients change some of their beliefs and understanding about asthma, and to improve asthma management with better education about the understanding of control for patients and HCPs.

背景:先前的研究已经发现患者对哮喘控制的感知与真实症状之间存在差异;尽管有几种假设,但原因尚不清楚。目的:探讨英国患者的哮喘症状和疾病管理经历及其教育需求;评估哮喘控制和管理的最新进展。方法:对英国18岁以上自述哮喘患者进行在线定量问卷调查。结果:在完成调查的1083人中(55%为女性,49%年龄>55岁),79%的人将他们的哮喘控制描述为“良好”或“非常好”。尽管如此,在过去的两年里,65%的人在白天出现“频繁”症状,37%的人在夜间出现“频繁”症状,25%的人使用口服类固醇治疗哮喘;41%的患者每天使用1次以上的缓解吸入器。总体而言,76%的人与他们的医疗保健专业人员(HCP)的关系“良好”或“非常好”;32%的人没有定期参加哮喘检查,只有12%的人使用个人哮喘行动计划。此外,70%的受访者认为他们对管理哮喘负有“主要责任”;29%的人认为这一责任与他们的HCP共同承担。结论:这项调查表明,患者对哮喘控制的感知与实际症状之间存在持续的差异,与以往的研究相比变化不大。许多病人认为症状是正常的。受访者态度的多样性表明,需要帮助患者改变他们对哮喘的一些信念和理解,并通过更好地教育患者和医务人员对控制的理解来改善哮喘管理。
{"title":"Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK.","authors":"Monica Fletcher,&nbsp;David Hiles","doi":"10.4104/pcrj.2013.00091","DOIUrl":"https://doi.org/10.4104/pcrj.2013.00091","url":null,"abstract":"<p><strong>Background: </strong>Previous studies have identified a discrepancy between patient perception of asthma control and real-world symptoms; despite several hypotheses, the reasons remain unclear.</p><p><strong>Aims: </strong>To explore patients' experiences of asthma symptoms and disease management and their educational needs in the UK; to assess recent progress in asthma control and management.</p><p><strong>Methods: </strong>A quantitative questionnaire-based online survey of UK patients aged >18 years with self-reported asthma.</p><p><strong>Results: </strong>Of the 1,083 individuals (55% female, 49% aged >55 years) who completed the survey, 79% described their asthma control as 'good' or 'very good'. Despite this, in the previous 2 years, 65% had experienced 'frequent' day-time symptoms, 37% had 'frequent' night-time symptoms, and 25% had used oral steroids for asthma; 41% of those prescribed a reliever inhaler used it >1 a day. Overall, 76% had a 'good' or 'very good' relationship with their healthcare professional (HCP); 32% had not attended regular asthma reviews and only 12% were using a personal asthma action plan. Moreover, 70% of respondents felt that they had the 'main responsibility' for managing their asthma; 29% believed this responsibility to be shared with their HCP.</p><p><strong>Conclusions: </strong>This survey indicates a continuing discrepancy between patient perception of asthma control and real-world symptoms, with little change from previous studies. Many patients accept symptoms as the norm. The diversity among respondents' attitudes demonstrates a need to help patients change some of their beliefs and understanding about asthma, and to improve asthma management with better education about the understanding of control for patients and HCPs.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31853681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
Correct inhalation technique is critical in achieving good asthma control. 正确的吸入技术是控制哮喘的关键。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00097
Federico Lavorini, Omar S Usmani
the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421. http://dx.doi.org/10.1086/313959 14. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F. Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2010;46(10):543-58. http://dx.doi.org/10.1016/j.arbres.2010.06.014 15. Woodhead M, Blasi F, Ewig S, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology and Infection 2011;17:(Suppl 6)
{"title":"Correct inhalation technique is critical in achieving good asthma control.","authors":"Federico Lavorini,&nbsp;Omar S Usmani","doi":"10.4104/pcrj.2013.00097","DOIUrl":"https://doi.org/10.4104/pcrj.2013.00097","url":null,"abstract":"the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421. http://dx.doi.org/10.1086/313959 14. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F. Community-Acquired Pneumonia. New Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2010;46(10):543-58. http://dx.doi.org/10.1016/j.arbres.2010.06.014 15. Woodhead M, Blasi F, Ewig S, et al. Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology and Infection 2011;17:(Suppl 6)","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00097","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31897440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 53
Using your bullets most wisely for the smoking gun. 为了找到确凿的证据,最明智地使用子弹。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00098
Keir Lewis
Everyone knows smoking is bad for you. It is the leading cause of preventable death and disability in developed and developing countries. Moreover, quitting smoking generates considerable benefits in both quantity and quality of life, almost irrespective of age at quitting. What is the role of doctors? As well as primary prevention, secondary and tertiary prevention to ease smoking-related suffering are increasingly important roles. As Schroeder points out, “Clinicians in general, and especially those who care for patients with smokingrelated illnesses (e.g., oncologists, cardiologists, pulmonologists, emergency physicians, psychiatrists and primary care physicians), should do more to stimulate quit attempts.” Calls for increased clinician efforts to reduce smoking are based on excellent evidence that doctor interventions really do help. Where, when, and how much intervention is most cost-effective, are all issues that need to be established. In developed countries, most people see their general practitioner (GP) every year, so primary care has a central role in population health. Pooled data from 17 trials of brief anti-smoking advice versus no advice (or usual care) confirms a significant increase in the rate of quitting (relative risk 1.66, 95% CI 1.42 to 1.94). Further metaanalysis of 35,000 smokers also shows a clear dose-dependent effect, with more quits following more intense intervention. However, (and crucially), these more successful intense interventions were defined as lasting longer than 10 minutes. Therefore the work reported by Neuner-Jehle et al. in this issue of the PCRJ, introducing an individualised counselling tool as a short intervention as ‘time sparingly as possible’, opens up good opportunities to increase both GP and patient awareness. During their 6-month study, 25 GPs randomised to the intervention of an additional visual, cardiac risk communication tool as well as the standard Opinion Sheet for smoking cessation from the IPCRG, performed on average 2.8 counselling sessions per month compared with 1.7 sessions per month by those GPs randomised to the standard IPCRG sheet alone. Although this was a 64% higher rate, the small numbers meant it was not statistically significant (p=0.3) despite their borderline non-inferiority power calculation. As things stand, it does not translate into clinically meaningful benefits, with no differences in patients’ motivation or satisfaction ratings between the two groups. Of course, also translating any increased motivation into quitting is the next hurdle. Their tool applied the concept of risk, and it is commendable that this risk was based on real-life clinical data from their own country, making it much more pertinent to their patients. Although applying Swiss cardiac risk could limit generalisability, their cardiac risk increase from smoking is similar to the international trials they quoted. In terms of limitations of their study, we would like to know more about the characteristi
{"title":"Using your bullets most wisely for the smoking gun.","authors":"Keir Lewis","doi":"10.4104/pcrj.2013.00098","DOIUrl":"https://doi.org/10.4104/pcrj.2013.00098","url":null,"abstract":"Everyone knows smoking is bad for you. It is the leading cause of preventable death and disability in developed and developing countries. Moreover, quitting smoking generates considerable benefits in both quantity and quality of life, almost irrespective of age at quitting. What is the role of doctors? As well as primary prevention, secondary and tertiary prevention to ease smoking-related suffering are increasingly important roles. As Schroeder points out, “Clinicians in general, and especially those who care for patients with smokingrelated illnesses (e.g., oncologists, cardiologists, pulmonologists, emergency physicians, psychiatrists and primary care physicians), should do more to stimulate quit attempts.” Calls for increased clinician efforts to reduce smoking are based on excellent evidence that doctor interventions really do help. Where, when, and how much intervention is most cost-effective, are all issues that need to be established. In developed countries, most people see their general practitioner (GP) every year, so primary care has a central role in population health. Pooled data from 17 trials of brief anti-smoking advice versus no advice (or usual care) confirms a significant increase in the rate of quitting (relative risk 1.66, 95% CI 1.42 to 1.94). Further metaanalysis of 35,000 smokers also shows a clear dose-dependent effect, with more quits following more intense intervention. However, (and crucially), these more successful intense interventions were defined as lasting longer than 10 minutes. Therefore the work reported by Neuner-Jehle et al. in this issue of the PCRJ, introducing an individualised counselling tool as a short intervention as ‘time sparingly as possible’, opens up good opportunities to increase both GP and patient awareness. During their 6-month study, 25 GPs randomised to the intervention of an additional visual, cardiac risk communication tool as well as the standard Opinion Sheet for smoking cessation from the IPCRG, performed on average 2.8 counselling sessions per month compared with 1.7 sessions per month by those GPs randomised to the standard IPCRG sheet alone. Although this was a 64% higher rate, the small numbers meant it was not statistically significant (p=0.3) despite their borderline non-inferiority power calculation. As things stand, it does not translate into clinically meaningful benefits, with no differences in patients’ motivation or satisfaction ratings between the two groups. Of course, also translating any increased motivation into quitting is the next hurdle. Their tool applied the concept of risk, and it is commendable that this risk was based on real-life clinical data from their own country, making it much more pertinent to their patients. Although applying Swiss cardiac risk could limit generalisability, their cardiac risk increase from smoking is similar to the international trials they quoted. In terms of limitations of their study, we would like to know more about the characteristi","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00098","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31924932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discrepancy between functional exercise capacity and daily physical activity: a cross-sectional study in patients with mild to moderate COPD. 功能锻炼能力与日常体力活动之间的差异:一项针对轻度至中度慢性阻塞性肺病患者的横断面研究。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00090
Annemieke Fastenau, Onno C P van Schayck, Rik Gosselink, Karin C P M Aretz, Jean W M Muris

Background: In patients with moderate to severe chronic obstructive pulmonary disease (COPD) the six-minute walk distance reflects the functional exercise level for daily physical activity. It is unknown if this also applies to patients with mild to moderate COPD in primary care.

Aims: To assess the relationship between functional exercise capacity and physical activity in patients with mild to moderate COPD.

Methods: A cross-sectional study was performed in 51 patients with mild to moderate COPD in primary care. Functional exercise capacity was assessed by the six-minute walk test and physical activity was measured with an accelerometer-based activity monitor.

Results: Functional exercise capacity was close to normal values. However, the daily physical activity of the patients could be classified as 'sedentary' and 'low active'. No significant correlations were observed between six-minute walk distance (% predicted) and any of the physical activity variables (steps per day, movement intensity during walking, total active time, total walking time, physical activity level, and time spent in moderate physical activity).

Conclusions: A discrepancy was found between functional exercise capacity and daily physical activity in patients with mild to moderate COPD recruited and assessed in primary care. We conclude that these variables represent two different concepts. Our results reinforce the importance of measuring daily physical activity in order to fine-tune treatment (i.e. focusing on enhancement of exercise capacity or behavioural change, or both).

背景:在中度至重度慢性阻塞性肺病(COPD)患者中,六分钟步行距离反映了日常体育活动的功能锻炼水平。目的:评估轻度至中度慢性阻塞性肺病患者的功能锻炼能力与体育锻炼之间的关系:方法:对 51 名轻度至中度慢性阻塞性肺病初级保健患者进行了横断面研究。功能锻炼能力通过六分钟步行测试进行评估,体力活动则通过加速度计活动监测仪进行测量:结果:功能锻炼能力接近正常值。然而,患者的日常体力活动可分为 "久坐 "和 "低活动量 "两类。六分钟步行距离(预测百分比)与任何体力活动变量(每天步数、步行时的运动强度、总活动时间、总步行时间、体力活动水平和中等体力活动时间)之间均未发现明显的相关性:结论:在基层医疗机构招募和评估的轻度至中度慢性阻塞性肺病患者中,发现功能锻炼能力和日常体力活动之间存在差异。我们的结论是,这些变量代表了两个不同的概念。我们的研究结果强化了测量日常体力活动的重要性,以便对治疗进行微调(即侧重于提高运动能力或改变行为,或两者兼顾)。
{"title":"Discrepancy between functional exercise capacity and daily physical activity: a cross-sectional study in patients with mild to moderate COPD.","authors":"Annemieke Fastenau, Onno C P van Schayck, Rik Gosselink, Karin C P M Aretz, Jean W M Muris","doi":"10.4104/pcrj.2013.00090","DOIUrl":"10.4104/pcrj.2013.00090","url":null,"abstract":"<p><strong>Background: </strong>In patients with moderate to severe chronic obstructive pulmonary disease (COPD) the six-minute walk distance reflects the functional exercise level for daily physical activity. It is unknown if this also applies to patients with mild to moderate COPD in primary care.</p><p><strong>Aims: </strong>To assess the relationship between functional exercise capacity and physical activity in patients with mild to moderate COPD.</p><p><strong>Methods: </strong>A cross-sectional study was performed in 51 patients with mild to moderate COPD in primary care. Functional exercise capacity was assessed by the six-minute walk test and physical activity was measured with an accelerometer-based activity monitor.</p><p><strong>Results: </strong>Functional exercise capacity was close to normal values. However, the daily physical activity of the patients could be classified as 'sedentary' and 'low active'. No significant correlations were observed between six-minute walk distance (% predicted) and any of the physical activity variables (steps per day, movement intensity during walking, total active time, total walking time, physical activity level, and time spent in moderate physical activity).</p><p><strong>Conclusions: </strong>A discrepancy was found between functional exercise capacity and daily physical activity in patients with mild to moderate COPD recruited and assessed in primary care. We conclude that these variables represent two different concepts. Our results reinforce the importance of measuring daily physical activity in order to fine-tune treatment (i.e. focusing on enhancement of exercise capacity or behavioural change, or both).</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31853682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
General practitioners' contribution to the management of community-acquired pneumonia in the Netherlands: a retrospective analysis of primary care, hospital, and national mortality databases with individual data linkage. 全科医生对荷兰社区获得性肺炎管理的贡献:对初级保健、医院和国家死亡率数据库的回顾性分析,并结合个人数据。
Pub Date : 2013-12-01 DOI: 10.4104/pcrj.2013.00085
Bianca Snijders, Wim van der Hoek, Irina Stirbu, Marianne A B van der Sande, Arianne B van Gageldonk-Lafeber

Background: Community-acquired pneumonia (CAP) is an important cause of hospital admission and death, but the extent of the problem of CAP at the primary healthcare level is largely unknown.

Aims: To investigate the contribution of general practitioners (GPs) to the management of patients with CAP in the Netherlands.

Methods: The study population consisted of all people enlisted in a GP network. We obtained information on CAP episodes from GP electronic records (using ICPC code R81) during the years 2002-2009. CAP registrations were also obtained from national hospital discharge data (ICD-9 codes) and cause of death statistics (ICD-10 codes). The three registration systems were linked at the individual level. We used descriptive analyses to estimate the annual number of CAP episodes (i.e. defined as a CAP diagnosis within 30 days).

Results: From 2002 to 2009 the mean annual size of the study population was 395,039. For this population, 3,700 (0.9%) CAP episodes per year were registered in at least one of the registration systems, 2,933 (79%) of which were in the GP system only. Recovery within 30 days occurred on average in 95% (2,791/2,933) of the CAP episodes annually registered by a GP, while 2.3% (67/2,933) of patients with a GP-registered CAP episode were admitted to hospital within 30 days and 1% (26/2,933) had a fatal outcome within 30 days.

Conclusions: The vast majority of CAP episodes registered in the Netherlands are managed successfully at the GP level without hospitalisation.

背景:社区获得性肺炎(CAP)是导致住院和死亡的重要原因,但CAP在初级保健层面的问题程度在很大程度上是未知的。目的:调查全科医生对荷兰CAP患者管理的贡献。方法:研究人群包括全科医生网络中的所有成员。我们从2002-2009年的全科医生电子记录(使用ICPC代码R81)中获得了CAP发作的信息。CAP登记还从国家出院数据(ICD-9代码)和死亡原因统计数据(ICD-10代码)中获得。这三个登记制度在个人一级是相互联系的。我们使用描述性分析来估计CAP发作的年数(即定义为30天内的CAP诊断)。结果:从2002年到2009年,研究人群的平均年规模为395039。对于这一人群,每年至少有3700例(0.9%)CAP发作在其中一个登记系统中登记,其中2933例(79%)仅在全科医生系统中登记。全科医生每年登记的CAP发作中,平均95%(2791/2933)在30天内康复,而2.3%(67/2933)的全科医生登记的CAP患者在30天之内入院,1%(26/2933。结论:在荷兰登记的绝大多数CAP发作在全科医生水平上都得到了成功的治疗,没有住院。
{"title":"General practitioners' contribution to the management of community-acquired pneumonia in the Netherlands: a retrospective analysis of primary care, hospital, and national mortality databases with individual data linkage.","authors":"Bianca Snijders,&nbsp;Wim van der Hoek,&nbsp;Irina Stirbu,&nbsp;Marianne A B van der Sande,&nbsp;Arianne B van Gageldonk-Lafeber","doi":"10.4104/pcrj.2013.00085","DOIUrl":"10.4104/pcrj.2013.00085","url":null,"abstract":"<p><strong>Background: </strong>Community-acquired pneumonia (CAP) is an important cause of hospital admission and death, but the extent of the problem of CAP at the primary healthcare level is largely unknown.</p><p><strong>Aims: </strong>To investigate the contribution of general practitioners (GPs) to the management of patients with CAP in the Netherlands.</p><p><strong>Methods: </strong>The study population consisted of all people enlisted in a GP network. We obtained information on CAP episodes from GP electronic records (using ICPC code R81) during the years 2002-2009. CAP registrations were also obtained from national hospital discharge data (ICD-9 codes) and cause of death statistics (ICD-10 codes). The three registration systems were linked at the individual level. We used descriptive analyses to estimate the annual number of CAP episodes (i.e. defined as a CAP diagnosis within 30 days).</p><p><strong>Results: </strong>From 2002 to 2009 the mean annual size of the study population was 395,039. For this population, 3,700 (0.9%) CAP episodes per year were registered in at least one of the registration systems, 2,933 (79%) of which were in the GP system only. Recovery within 30 days occurred on average in 95% (2,791/2,933) of the CAP episodes annually registered by a GP, while 2.3% (67/2,933) of patients with a GP-registered CAP episode were admitted to hospital within 30 days and 1% (26/2,933) had a fatal outcome within 30 days.</p><p><strong>Conclusions: </strong>The vast majority of CAP episodes registered in the Netherlands are managed successfully at the GP level without hospitalisation.</p>","PeriodicalId":48998,"journal":{"name":"Primary Care Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4104/pcrj.2013.00085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31737976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
期刊
Primary Care Respiratory Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1